Page last updated: 2024-10-27

flutamide and Obesity

flutamide has been researched along with Obesity in 12 studies

Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome."9.12Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006)
"Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)."9.11Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004)
" The objective of this study was to treat aging (7-8 months) +/- follicle-stimulating hormone receptor mice that are destined for reproductive failure with 2 selected antiandrogens, curcumin and flutamide, to counteract deleterious effects of mild hyperandrogenemia on the ovary and metabolism."7.75Modulation of ovarian structure and abdominal obesity in curcumin- and flutamide-treated aging FSH-R haploinsufficient mice. ( Ram Sairam, M; Tiwari-Pandey, R, 2009)
"The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33."7.72Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004)
"Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0."5.30The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998)
"The few controlled trials performed so far indicate that the addition of metformin and/or flutamide to a hypocaloric diet in obese women with polycystic ovary syndrome (PCOS) effectively influences different phenotypic aspects of the syndrome."5.12Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. ( Cacciari, M; Cavazza, C; Gambineri, A; Morselli-Labate, AM; Pagotto, U; Pasquali, R; Patton, L; Vaccina, A, 2006)
"Low-dose flutamide-metformin has been developed as a background therapy for non-obese adolescents and young women with hyperinsulinaemic hyperandrogenism, a variant of polycystic ovary syndrome (PCOS)."5.11Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity. ( De Zegher, F; Ibáñez, L, 2004)
" To distinguish the mechanisms of this association, we determined the interactions of PCO with obesity and the influence of ameliorating direct androgenic actions via short-term treatment with the antiandrogen flutamide."5.08Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Georgiadou, E; Hennes, MM; Hoffmann, RG; Kaklas, N; Kissebah, AH; Mitrakou, A; Platanissiotis, D; Raptis, S; Spina, J, 1995)
" This study tested whether 1) in utero cotreatment of prenatally T-treated sheep with androgen antagonist (flutamide) or insulin sensitizer (rosiglitazone) prevents juvenile insulin resistance and adult changes in adipocyte size; and 2) visceral adiposity and insulin sensitivity are both unaltered during early adulthood, confirming the predicted developmental trajectory in this animal model."3.83Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep. ( Beckett, E; Cardoso, RC; Chazenbalk, G; Dumesic, D; Keller, E; Madrigal, V; Moeller, J; Padmanabhan, V; Pease, A; Veiga-Lopez, A, 2016)
"The authors evaluate the effects of 2 months of treatment with 250 mg flutamide daily on adrenal steroidogenesis (ACTH test) and metabolic parameters (lipids, insulin resistance) in 12 PCOS women aged 33."3.72Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome. ( Dvoráková, K; Hill, M; Stanická, S; Stárka, L; Vondra, K; Vrbíková, J, 2004)
"Hirsutism is the manifestation of hyperandrogenemia in PCOS."1.32The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004)
"Flutamide treatment was also associated with a trend toward an increase in HDL (by 14%; P = 0."1.30The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. ( Diamanti-Kandarakis, E; Duleba, AJ; Mitrakou, A; Raptis, S; Tolis, G, 1998)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (25.00)18.2507
2000's7 (58.33)29.6817
2010's2 (16.67)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ibáñez, L2
Ong, KK1
López-Bermejo, A1
Dunger, DB1
de Zegher, F2
Cardoso, RC1
Veiga-Lopez, A1
Moeller, J1
Beckett, E1
Pease, A1
Keller, E1
Madrigal, V1
Chazenbalk, G1
Dumesic, D1
Padmanabhan, V1
Tiwari-Pandey, R1
Ram Sairam, M1
Gambineri, A3
Pagotto, U3
Tschöp, M1
Vicennati, V1
Manicardi, E1
Carcello, A1
Cacciari, M3
De Iasio, R1
Pasquali, R3
Pelusi, C1
Genghini, S1
Morselli-Labate, AM2
Ajossa, S1
Guerriero, S1
Paoletti, AM1
Orrù, M1
Melis, GB1
Vrbíková, J1
Hill, M1
Dvoráková, K1
Stanická, S1
Vondra, K1
Stárka, L1
Patton, L1
Vaccina, A1
Cavazza, C1
deKernion, JB1
Diamanti-Kandarakis, E2
Mitrakou, A2
Hennes, MM1
Platanissiotis, D1
Kaklas, N1
Spina, J1
Georgiadou, E1
Hoffmann, RG1
Kissebah, AH1
Raptis, S2
Tolis, G1
Duleba, AJ1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471]45 participants (Anticipated)Observational2021-06-30Not yet recruiting
Metabolic Syndrome in PCOS: Precursors and Interventions[NCT00442689]97 participants (Actual)Interventional2006-07-31Completed
Pilot Trial of Bicalutamide Versus Placebo in Reproductive-Aged Women With Nonalcoholic Fatty Liver Disease (NAFLD) and Polycystic Ovary Syndrome (PCOS)[NCT05979389]Phase 150 participants (Anticipated)Interventional2023-12-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Disposition Index

Change in disposition index (DI, insulin secretion corrected for insulin secretion) as measured by frequently-sampled IV glucose tolerance test (DI at study endpoint - baseline DI) (NCT00442689)
Timeframe: 6 months

Interventionmin^-1 (Mean)
Oral Contraceptive - 11653
Flutamide - 2194
Placebo - 3-184

Change in Fat Percentage as Measured by Dual-energy X-ray Absorptiometry (DEXA) Scan Over the Study Period

Change in fat percentage as measured by DEXA scan over the study period (Fat percentage at study endpoint - baseline fat percentage) (NCT00442689)
Timeframe: 6 months

Interventionpercentage of body mass (Mean)
Oral Contraceptive - 10.4
Flutamide - 2-1.9
Placebo - 3-1.9

Change in High-density Lipoprotein (HDL) Levels During Study Period

Change in high-density lipoprotein (HDL) levels during study period (HDL level at study endpoint - baseline HDL) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 16
Flutamide - 2-5
Placebo - 3-2

Change in Low-density Lipoprotein (LDL) Levels Over the Study Period

Change in low-density lipoprotein (LDL) levels over the study period (LDL level at study endpoint - baseline LDL level) (NCT00442689)
Timeframe: 6 months

Interventionmg/dL (Mean)
Oral Contraceptive - 1-6
Flutamide - 2-9
Placebo - 3-7

Change in Maximal Aerobic Exercise Capacity (VO2 Max) Over the Study Period

Change in maximal aerobic exercise capacity (VO2 max) over the study period (VO2 max at study endpoint - baseline VO2 max) (NCT00442689)
Timeframe: 6 months

InterventionL/min (Mean)
Oral Contraceptive - 1-0.5
Flutamide - 2-1.6
Placebo - 31.1

Change in Resting Energy Expenditure (REE) Over the Study Period

Change in resting energy expenditure (REE) over the study period (REE at study endpoint - baseline REE) (NCT00442689)
Timeframe: 6 months

InterventionKcal/day (Mean)
Oral Contraceptive - 17
Flutamide - 2-79
Placebo - 3-88

Change in Visceral Adipose Tissue (VAT) Volume as Measured by MRI

Change in visceral adipose tissue (VAT) volume as measured by MRI (VAT at study endpoint - baseline VAT) (NCT00442689)
Timeframe: 6 months

InterventionL (Mean)
Oral Contraceptive - 1-0.1
Flutamide - 2-0.1
Placebo - 30.1

Trials

5 trials available for flutamide and Obesity

ArticleYear
Anti-androgen treatment increases circulating ghrelin levels in obese women with polycystic ovary syndrome.
    Journal of endocrinological investigation, 2003, Volume: 26, Issue:7

    Topics: Adult; Androgen Antagonists; Androstenedione; Blood Glucose; Body Composition; Body Weight; Female;

2003
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Clinical endocrinology, 2004, Volume: 60, Issue:2

    Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T

2004
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Clinical endocrinology, 2004, Volume: 60, Issue:2

    Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T

2004
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Clinical endocrinology, 2004, Volume: 60, Issue:2

    Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T

2004
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome.
    Clinical endocrinology, 2004, Volume: 60, Issue:2

    Topics: Adult; Analysis of Variance; Androgen Antagonists; Combined Modality Therapy; Diet, Reducing; Drug T

2004
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
    Human reproduction (Oxford, England), 2004, Volume: 19, Issue:8

    Topics: Abdomen; Adipose Tissue; Adolescent; Adult; Androgen Antagonists; Contraceptives, Oral; Drug Therapy

2004
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide;

2006
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide;

2006
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide;

2006
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study.
    The Journal of clinical endocrinology and metabolism, 2006, Volume: 91, Issue:10

    Topics: Adipose Tissue; Adult; Diet, Reducing; Drug Therapy, Combination; Energy Intake; Female; Flutamide;

2006
Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome.
    Metabolism: clinical and experimental, 1995, Volume: 44, Issue:4

    Topics: Adolescent; Adult; Androgen Antagonists; Androgens; Female; Flutamide; Humans; Insulin Resistance; O

1995

Other Studies

7 other studies available for flutamide and Obesity

ArticleYear
Hyperinsulinaemic androgen excess in adolescent girls.
    Nature reviews. Endocrinology, 2014, Volume: 10, Issue:8

    Topics: Adolescent; Androgens; Drug Therapy, Combination; Dyslipidemias; Female; Flutamide; Hirsutism; Human

2014
Developmental Programming: Impact of Gestational Steroid and Metabolic Milieus on Adiposity and Insulin Sensitivity in Prenatal Testosterone-Treated Female Sheep.
    Endocrinology, 2016, Volume: 157, Issue:2

    Topics: Adiposity; Animals; Disease Models, Animal; Embryonic Development; Female; Flutamide; Insulin Resist

2016
Modulation of ovarian structure and abdominal obesity in curcumin- and flutamide-treated aging FSH-R haploinsufficient mice.
    Reproductive sciences (Thousand Oaks, Calif.), 2009, Volume: 16, Issue:6

    Topics: Abdominal Fat; Aging; Animals; Curcumin; Female; Flutamide; Haploidy; Mice; Mice, Transgenic; Obesit

2009
The treatment of polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate;

2004
Flutamide suppresses adrenal steroidogenesis but has no effect on insulin resistance and secretion and lipid levels in overweight women with polycystic ovary syndrome.
    Gynecologic and obstetric investigation, 2004, Volume: 58, Issue:1

    Topics: 17-Hydroxysteroid Dehydrogenases; Adrenal Glands; Adrenocorticotropic Hormone; Adult; Androgen Antag

2004
Prostate cancer.
    The Journal of urology, 1996, Volume: 155, Issue:1

    Topics: Androgen Antagonists; Antineoplastic Agents; Chemotherapy, Adjuvant; Flutamide; Humans; Male; Obesit

1996
The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome.
    The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:8

    Topics: Adult; Androgen Antagonists; Androstane-3,17-diol; Androstenedione; Cholesterol; Dehydroepiandroster

1998